세계의 중간엽 줄기세포 시장 - 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 워크플로우 유형별, 유형별, 분리원별, 적응증별, 용도별, 지역별 부문 예측(2024-2030년)

Mesenchymal Stem Cells Market Growth & Trends:

The global mesenchymal stem cells (MSC) market size is expected to reach USD 7.27 billion by 2030, expanding at a CAGR of 12.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. An exponential increase in Mesenchymal Stem Cell (MSC) based research and its implications in the field of regenerative medicine is anticipated to fuel the industry expansion. Moreover, the constantly evolving landscape of cell therapies is also anticipated to propel investments in the mesenchymal stem cells market space; large-scale operational firms are targeting small or emerging players with an operating strategy of acquisition to bolster their market presence.

The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the industry growth. For instance, in 2022, the U.S. FDA has approved around 19 stem cell therapies for range of life-threatening disorders. Some of these therapies include, BREYANZI of BMS, ALLOCORD, KYMIRAH of Novartis etc. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutic regime for the management of inflammatory conditions, in turn, boosting market growth.

For instance, on January 2022, the Century Therapeutics and Bristol Myers Squibb entered a collaboration to expand IPSC-derives allogenic cell therapies. In addition, Takeda/TiGenix phase 3 clinical trial incorporated mesenchymal stem cells for complex perianal fistulas in Crohn's Disease. This was the most successful late-stage clinical trial as of September 2020. In addition, in August 2022 AGC Biologics partnered with human mesenchymal stem cell supplier, RoosterBio Inc. to deliver clinically proven advanced therapies for life-threatening conditions. These factors are projected to bolster the usage of stem cell products offered by key entities, thereby intensifying the market competition.

Market players are focused on the expansion of their offerings through extensive R&D and the formation of alliances and partnerships with other major players to sustain their market position. Owing to the recent pandemic of COVID-19, several research and academic research institutes are making focused efforts to develop a treatment regime by using mesenchymal stem cells.

Mesenchymal Stem Cells Market Report Highlights:

• The products segment dominated the segment and accounted for the largest revenue share of 78.89% in 2023. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment's revenue
• Based on workflow type, the culture and cryopreservation segment dominated the industry with revenue share of 44.55% in 2023. The segment growth is attributed to the high demand for cryopreservation services and enhancement of healthcare infrastructure in developing economies
• The allogenic MSCs segment accounted for the higher revenue share of 56.60% in 2023. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications
• The bone marrow segment dominated the market and accounted for the largest revenue share of 24.56% in 2023. Bone marrow is a major source of isolation for mesenchymal cells
• The disease modelling application segment dominated the application and accounted for the largest revenue share of 35.23% in 2023. The use of cellular disease models with patient specific MSCs provides an ideal tool for pathological research
• North America dominated the market and accounted for the largest revenue share of 45.11% in 2023. The higher revenue share of the region is accounted to supportive government legislation and rising application of cell therapies in chronic disorders

Table of Contents

Chapter 1. Mesenchymal Stem Cells Market: Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information Or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share
  • 1.4.2. Regional Analysis

Chapter 2. Mesenchymal Stem Cells Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Mesenchymal Stem Cells Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expanding pipeline and clinical studies of mesenchymal stem cell based products
    • 3.2.1.2. Emerging applications of MSCs
    • 3.2.1.3. Rising market competition among key players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardized & regulated delivery of stem cell therapy
    • 3.2.2.2. Ethical & safety concerns controversies associated with human msc therapy
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

• 4.1. Product & Services Segment Dashboard
• 4.2. Mesenchymal Stem Cells Market Product & Services Movement Analysis
• 4.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
• 4.4. Products
  • 4.4.1. Products market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Cell & Cell Lines
    • 4.4.2.1. Cell & cell lines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Kits, Media, & Reagents
    • 4.4.3.1. Kits, media, & reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Workflow Business Analysis

• 5.1. Workflow Segment Dashboard
• 5.2. Mesenchymal Stem Cells Market Workflow Movement Analysis
• 5.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 5.4. Cell Sourcing & Isolation
  • 5.4.1. Cell sourcing & isolation market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Culture & Cryopreservation
  • 5.5.1. Culture & cryopreservation market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Differentiation
  • 5.6.1. Differentiation market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Characterization
  • 5.7.1. Characterization market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Type Business Analysis

• 6.1. Type Segment Dashboard
• 6.2. Mesenchymal Stem Cells Market Type Movement Analysis
• 6.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Autologous
  • 6.4.1. Autologous market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Allogeneic
  • 6.5.1. Allogeneic market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Source of Isolation Business Analysis

• 7.1. Source of Isolation Segment Dashboard
• 7.2. Mesenchymal Stem Cells Market Source of Isolation Movement Analysis
• 7.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Source of Isolation, 2018 to 2030 (USD Million)
• 7.4. Bone Marrow
  • 7.4.1. Bone marrow market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Cord Blood
  • 7.5.1. Cord blood market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.6. Peripheral Blood
  • 7.6.1. Peripheral blood market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.7. Fallopian Tube
  • 7.7.1. Fallopian tube market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.8. Fetal Liver
  • 7.8.1. Fetal liver market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.9. Lung
  • 7.9.1. Lung market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.10. Adipose Tissues
  • 7.10.1. Adipose tissues market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Indication Business Analysis

• 8.1. Indication Segment Dashboard
• 8.2. Mesenchymal Stem Cells Market Indication Movement Analysis
• 8.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 8.4. Bone & Cartilage Repair
  • 8.4.1. Bone & cartilage repair market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Cardiovascular Disease
  • 8.5.1. Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Inflammatory & Immunological Diseases
  • 8.6.1. Inflammatory & immunological diseases market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.7. Liver Diseases
  • 8.7.1. Liver diseases market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.8. Cancer
  • 8.8.1. Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.9. GvHD
  • 8.9.1. GvHD market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.10. Others
  • 8.10.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Application Business Analysis

• 9.1. Application Segment Dashboard
• 9.2. Mesenchymal Stem Cells Market Application Movement Analysis
• 9.3. Mesenchymal Stem Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 9.4. Disease Modeling
  • 9.4.1. Disease modeling market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Drug Development & Discovery
  • 9.5.1. Drug development & discovery market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Stem Cell Banking
  • 9.6.1. Stem cell banking market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.7. Tissue Engineering
  • 9.7.1. Tissue engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.8. Toxicology Studies
  • 9.8.1. Toxicology studies market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.9. Others
  • 9.9.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Regional Business Analysis by Product & Services, Workflow Type, Type, Source of Isolation, Indication, and Application

• 10.1. Regional Dashboard
• 10.2. Market Size & Forecast and Trend Analysis, 2023 & 2030
• 10.3. North America
  • 10.3.1. North America Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.3.2. U.S.
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Target Disease Prevalence
    • 10.3.2.4. U.S. Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Target Disease Prevalence
    • 10.3.3.4. Canada Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.2. UK
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Target Disease Prevalence
    • 10.4.2.4. UK Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Target Disease Prevalence
    • 10.4.3.4. Germany Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Target Disease Prevalence
    • 10.4.4.4. France Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Target Disease Prevalence
    • 10.4.5.4. Italy Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Target Disease Prevalence
    • 10.4.6.4. Spain Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Target Disease Prevalence
    • 10.4.7.4. Denmark Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Target Disease Prevalence
    • 10.4.8.4. Sweden Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Target Disease Prevalence
    • 10.4.9.4. Norway Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.2. Japan
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Target Disease Prevalence
    • 10.5.2.4. Japan Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.3. China
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Target Disease Prevalence
    • 10.5.3.4. China Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Target Disease Prevalence
    • 10.5.4.4. India Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.5. Australia
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Target Disease Prevalence
    • 10.5.5.4. Australia Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.6. Thailand
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Target Disease Prevalence
    • 10.5.6.4. Thailand Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.5.7. South Korea
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Target Disease Prevalence
    • 10.5.7.4. South Korea Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Target Disease Prevalence
    • 10.6.2.4. Brazil Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.6.3. Mexico
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Target Disease Prevalence
    • 10.6.3.4. Mexico Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.6.4. Argentina
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Competitive Scenario
    • 10.6.4.3. Target Disease Prevalence
    • 10.6.4.4. Argentina Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
• 10.7. MEA
  • 10.7.1. MEA Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.7.2. South Africa
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Target Disease Prevalence
    • 10.7.2.4. South Africa Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.7.3. Saudi Arabia
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Target Disease Prevalence
    • 10.7.3.4. Saudi Arabia Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.7.4. UAE
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Target Disease Prevalence
    • 10.7.4.4. UAE Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Target Disease Prevalence
    • 10.7.5.4. Kuwait Mesenchymal Stem Cells Market, 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
• 11.2. Strategy Mapping
• 11.3. Company Market Position Analysis, 2023
• 11.4. Company Profiles/Listing
  • 11.4.1. Thermo Fisher Scientific, Inc.
    • 11.4.1.1. Overview
    • 11.4.1.2. Financial Performance
    • 11.4.1.3. Product Benchmarking
    • 11.4.1.4. Strategic Initiatives
  • 11.4.2. Cell Applications, Inc.
    • 11.4.2.1. Overview
    • 11.4.2.2. Product Benchmarking
    • 11.4.2.3. Strategic Initiatives
  • 11.4.3. Cyagen Biosciences
    • 11.4.3.1. Overview
    • 11.4.3.2. Product Benchmarking
    • 11.4.3.3. Strategic Initiatives
  • 11.4.4. Axol Bioscience Ltd.
    • 11.4.4.1. Overview
    • 11.4.4.2. Product Benchmarking
    • 11.4.4.3. Strategic Initiatives
  • 11.4.5. STEMCELL Technologies
    • 11.4.5.1. Overview
    • 11.4.5.2. Product Benchmarking
    • 11.4.5.3. Strategic Initiatives
  • 11.4.6. Celprogen Inc.
    • 11.4.6.1. Overview
    • 11.4.6.2. Product Benchmarking
    • 11.4.6.3. Strategic Initiatives
  • 11.4.7. Cellcolabs
    • 11.4.7.1. Overview
    • 11.4.7.2. Product Benchmarking
    • 11.4.7.3. Strategic Initiatives
  • 11.4.8. Stemedica Cell Technologies, Inc.
    • 11.4.8.1. Overview
    • 11.4.8.2. Product Benchmarking
    • 11.4.8.3. Strategic Initiatives
  • 11.4.9. Merck KGaA
    • 11.4.9.1. Overview
    • 11.4.9.2. Financial Performance
    • 11.4.9.3. Product Benchmarking
    • 11.4.9.4. Strategic Initiatives
  • 11.4.10. Lonza
    • 11.4.10.1. Overview
    • 11.4.10.2. Financial Performance
    • 11.4.10.3. Product Benchmarking
    • 11.4.10.4. Strategic Initiatives
  • 11.4.11. PromoCell GmbH
    • 11.4.11.1. Overview
    • 11.4.11.2. Product Benchmarking
    • 11.4.11.3. Strategic Initiatives